Based on the information available, there is potential risk in receiving live vaccines during Cosentyx (secukinumab) therapy. Cosentyx is a medication used to treat several conditions, such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. It is a type of drug known as a monoclonal antibody, which works by targeting and blocking a specific protein in the body (interleukin-17A) that contributes to inflammation [1].

According to the Cosentyx prescribing information, live vaccines should be avoided in patients receiving Cosentyx due to the potential risk of developing infections [1]. The rationale behind this recommendation is that Cosentyx may affect the immune system's ability to respond effectively to live vaccines, increasing the risk of vaccine-related infections [1].

It is essential to consult with a healthcare professional before receiving any vaccinations while on Cosentyx therapy. They will assess the potential risks and benefits and determine the most appropriate course of action based on individual patient circumstances [1].

In summary, there is a potential risk in receiving live vaccines during Cosentyx therapy. Patients should consult their healthcare professionals before receiving any vaccinations while on this medication.

Sources:
[1] Novartis Pharmaceuticals Corporation. (2021). Cosentyx (secukinumab) [Prescribing Information]. Retrieved from <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>
[2] DrugPatentWatch.com. (n.d.). Cosentyx (secukinumab) Drug Patent Information. Retrieved from <https://www.drugpatentwatch.com/drugs/cosentyx>